{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T06:08:44Z","timestamp":1777702124308,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology Nursing"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.soncn.2024.151628","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T11:24:43Z","timestamp":1712575483000},"page":"151628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advanced Practice Nursing and CAR-T Cell Therapy: Opportunities, Challenges and Future Directions"],"prefix":"10.1016","volume":"40","author":[{"given":"Daniel","family":"Kisielewski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3169-1812","authenticated-orcid":false,"given":"Matthias","family":"Naegele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.soncn.2024.151628_bib0001","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood.V120.21.3972.3972","article-title":"Continued improvement in survival in multiple myeloma and the impact of novel agents","volume":"120","author":"Kumar","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.soncn.2024.151628_bib0002","doi-asserted-by":"crossref","first-page":"E79","DOI":"10.1188\/17.CJON.E79-E86","article-title":"CAR T-cell therapy effects: review of procedures and patient education","volume":"21","author":"McConville","year":"2017","journal-title":"Clin J Oncol Nurs"},{"issue":"10","key":"10.1016\/j.soncn.2024.151628_bib0003","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.soncn.2024.151628_bib0004","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.soncn.2024.151628_bib0005","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the myeloma CAR T consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.soncn.2024.151628_bib0006","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.soncn.2024.151628_bib0007","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.soncn.2024.151628_bib0008","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1111\/bcp.14403","article-title":"Chimeric antigen receptor T-cell therapy toxicities","volume":"87","author":"Greenbaum","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.soncn.2024.151628_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.soncn.2021.151178","article-title":"Tisagenlecleucel therapy: nursing considerations for the outpatient setting","volume":"37","author":"Cunningham","year":"2021","journal-title":"Semin Oncol Nurs"},{"issue":"6","key":"10.1016\/j.soncn.2024.151628_bib0010","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/bjh.18339","article-title":"Feasibility of outpatient administration of axicabtagene ciloleucel and brexucabtagene autoleucel using telemedicine tools: the Vanderbilt experience","volume":"198","author":"Dholaria","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.soncn.2024.151628_bib0011","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-T in large B-cell lymphoma\u2014the UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.soncn.2024.151628_bib0012","first-page":"2","article-title":"Chronic disease management: what will it take to improve care for chronic illness?","volume":"1","author":"Wagner","year":"1998","journal-title":"Eff Clin Pract"},{"key":"10.1016\/j.soncn.2024.151628_bib0013","series-title":"Soziologie von Gesundheit und Krankheit","first-page":"243","article-title":"Bew\u00e4ltigung chronischer Krankheit","author":"Schaeffer","year":"2016"},{"key":"10.1016\/j.soncn.2024.151628_bib0014","series-title":"Hamric and Hanson's Advanced Practice Nursing: An Integrative Approach","author":"Tracy","year":"2018"},{"issue":"5","key":"10.1016\/j.soncn.2024.151628_bib0015","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1024\/1012-5302\/a000825","article-title":"Betreuung durch ein Advanced Nursing Practice-Team\u2014Erfahrungen Lymphombetroffener und ihrer Angeh\u00f6rigen: Eine qualitative Studie","volume":"34","author":"Bachofner","year":"2021","journal-title":"Pflege"},{"key":"10.1016\/j.soncn.2024.151628_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2021.100303","article-title":"Experiences and perspectives of individuals accessing CAR-T cell therapy: a qualitative analysis of online Reddit discussions","volume":"30","author":"Jenei","year":"2021","journal-title":"J Cancer Policy"},{"issue":"5","key":"10.1016\/j.soncn.2024.151628_bib0017","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00520-023-07763-x","article-title":"Patients\u2019 experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study","volume":"31","author":"Mao","year":"2023","journal-title":"Support Care Cancer"},{"issue":"2","key":"10.1016\/j.soncn.2024.151628_bib0018","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/02692163221138880","article-title":"A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: recommendations for service development and implications for palliative care teams","volume":"37","author":"Stenson","year":"2023","journal-title":"Palliat Med"},{"key":"10.1016\/j.soncn.2024.151628_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107074","article-title":"Analysis of patient-reported experiences up to 2 years after receiving idecabtagene vicleucel (ide-cel, bb2121) for relapsed or refractory multiple myeloma: longitudinal findings from the phase 2 KarMMa trial","volume":"129","author":"Delforge","year":"2023","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.soncn.2024.151628_bib0020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/bloodadvances.2019001026","article-title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.soncn.2024.151628_bib0021","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/cncr.34557","article-title":"Perception of prognosis, quality of life, and distress in patients receiving chimeric antigen receptor T-cell therapy","volume":"129","author":"Dhawale","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.soncn.2024.151628_bib0022","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.soncn.2024.151628_bib0023","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","article-title":"Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.soncn.2024.151628_bib0024","doi-asserted-by":"crossref","first-page":"930.e1","DOI":"10.1016\/j.jtct.2021.07.007","article-title":"Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.soncn.2024.151628_bib0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40487-021-00174-0","article-title":"Patient perspectives on health-related quality of life in diffuse large B-cell lymphoma treated with CAR T-cell therapy: a qualitative study","volume":"10","author":"Cheng","year":"2022","journal-title":"Oncol Ther"},{"issue":"8","key":"10.1016\/j.soncn.2024.151628_bib0026","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/pon.5674","article-title":"Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy","volume":"30","author":"Barata","year":"2021","journal-title":"Psychooncology"},{"issue":"3","key":"10.1016\/j.soncn.2024.151628_bib0027","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1188\/21.CJON.255-258","article-title":"CAR T-cell therapy: updates in nursing management","volume":"25","author":"Baer","year":"2021","journal-title":"Clin J Oncol Nurs"},{"issue":"1","key":"10.1016\/j.soncn.2024.151628_bib0028","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13023-023-02680-y","article-title":"\u201cI just wanted to speak to someone- and there was no one\u2026\u201d: using burden of treatment theory to understand the impact of a novel ATMP on early recipients","volume":"18","author":"Litchfield","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"14","key":"10.1016\/j.soncn.2024.151628_bib0029","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1182\/bloodadvances.2022009117","article-title":"Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy","volume":"7","author":"Johnson","year":"2023","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.soncn.2024.151628_bib0030","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.2022015478","article-title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","volume":"140","author":"Elsawy","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.soncn.2024.151628_bib0031","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1007\/s00432-023-04818-8","article-title":"Systematic symptom screening in patients with advanced cancer treated in certified oncology centers: results of the prospective multicenter German KeSBa project","volume":"149","author":"Braulke","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.soncn.2024.151628_bib0032","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S2352-3026(20)30033-8","article-title":"Nursing impact on the CAR-T cell landscape","volume":"7","author":"McDermott","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.soncn.2024.151628_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejon.2023.102407","article-title":"Patients\u2019 and professionals\u2019 experiences with advanced practice nursing in cancer care: a qualitative study","volume":"66","author":"Serra-Barril","year":"2023","journal-title":"Eur J Oncol Nurs"},{"issue":"2","key":"10.1016\/j.soncn.2024.151628_bib0034","first-page":"20","article-title":"Building a program: implications for infrastructure, nursing education, and training for CAR T-cell therapy","volume":"23","author":"Taylor","year":"2019","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.soncn.2024.151628_bib0035","unstructured":"IMF Nurse Leadership Board. Discussion with IMF Nurse Leadership Board: the potential of CAR-T therapy and the myeloma patient journey. 2018. Accessed May 27, 2022. Available at: https:\/\/s3.us-west-1.wasabisys.com\/imf-d8-prod\/resource\/CAR-T%20therapy%20in%20Myeloma%205.1.19.pdf"},{"issue":"11","key":"10.1016\/j.soncn.2024.151628_bib0036","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T cell therapy for solid tumors: bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.soncn.2024.151628_bib0037","unstructured":"IMF Nurse Leadership Board. Discussion with IMF Nurse Leadership Board: Ciltacabtagene Autoleucel: insights on chimeric antigen receptor T-Cell therapy efficacy, safety, and management approaches. 2021. Accessed January 28, 2024. Available at: https:\/\/imf-d8-prod.s3.us-west-1.wasabisys.com\/2021-10\/Cilta-cel-a-CAR-T-in-Multiple-Myeloma.pdf"},{"key":"10.1016\/j.soncn.2024.151628_bib0038","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40487-023-00232-9","article-title":"Patient perceptions of CAR-T therapy in the USA: findings from in-depth interviews","volume":"11","author":"Bixby","year":"2023","journal-title":"Oncol Ther"}],"container-title":["Seminars in Oncology Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208124000676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749208124000676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T10:13:27Z","timestamp":1733220807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749208124000676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0749208124000676"],"URL":"https:\/\/doi.org\/10.1016\/j.soncn.2024.151628","relation":{},"ISSN":["0749-2081"],"issn-type":[{"value":"0749-2081","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced Practice Nursing and CAR-T Cell Therapy: Opportunities, Challenges and Future Directions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology Nursing","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soncn.2024.151628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151628"}}